The trials were generally small, short and geographically concentrated, and none measured cardiovascular events, so the results concern blood lipid markers rather than proven clinical protection against heart disease or stroke. The analysis, registered prospectively and conducted in line with systematic-review guidance, searched five electronic databases from their inception through March 6, 2026, and also examined references and citations. Eleven included studies used parallel-group designs and two used crossover designs.

The participants included adults with type 2 diabetes, hyperlipidemia, hemodialysis, knee osteoarthritis, rheumatoid arthritis or non-alcoholic fatty liver disease, as well as healthy postmenopausal women, overweight or obese adults with at least one metabolic risk factor, and otherwise healthy adults with slightly elevated LDL cholesterol. Interventions included whole or ground sesame seeds, sesame oil and 200-milligram sesamin capsules, while controls ranged from matched placebos and usual diets to sunflower oil. The pooled reduction in total cholesterol was statistically significant, with a mean difference of −11.65 milligrams per deciliter and a 95% confidence interval from −18.73 to −4.57.

Statistical heterogeneity was moderate at 57.7%. The result was significant among trials using sesame oil or seed, which showed a reduction of 10.86 milligrams per deciliter, but not in the two sesamin trials, whose point estimate was larger but highly uncertain. Both healthy participants and those with medical conditions showed significant reductions, and formal tests did not establish that the two groups differed.

The total-cholesterol estimate remained statistically significant when individual studies were removed in sensitivity analyses, although excluding one high-risk-of-bias trial attenuated it to 8.21 milligrams per deciliter. LDL cholesterol produced the review’s most consistent lipid finding. Sesame-based interventions led to a pooled reduction of 9.14 milligrams per deciliter, with a 95% confidence interval of −14.40 to −3.89 and moderate heterogeneity of 44.0%.

The estimate remained statistically significant after any single trial was omitted and remained significant after two studies using sunflower oil as the comparator were excluded. Subgroup estimates were similar in healthy participants and those with medical conditions. As with total cholesterol, statistically significant reductions were confined to interventions lasting at least eight weeks, but the formal difference between shorter and longer trials did not meet the threshold for a definitive subgroup effect.

Triglycerides did not change significantly overall. The pooled difference was −14.15 milligrams per deciliter, but its 95% confidence interval extended from −29.04 to 0.74 and heterogeneity was substantial at 63.4%. The result was sensitive to the removal of individual studies, illustrating the limited stability of the pooled estimate.

Trials involving participants with medical conditions showed a significant reduction of 22.79 milligrams per deciliter, whereas the three estimates in healthy participants indicated a small, nonsignificant change in the opposite direction. Because the difference between groups was borderline, the analysis included only three healthy estimates, and the groups also differed in baseline triglycerides and intervention characteristics, the reviewers treated this pattern as hypothesis-generating rather than proof of a distinct response by health status. Sesame also had no significant overall effect on HDL cholesterol, with a mean difference of 0.38 milligrams per deciliter and a 95% confidence interval of −1.62 to 2.38.

A small increase appeared in trials lasting fewer than eight weeks, while longer trials showed no change. Although the formal test for this duration difference was nominally significant, the review treated it cautiously because the analysis included multiple subgroup comparisons across four lipid outcomes, increasing the possibility of chance findings. The investigators also found no consistent concentration-response relationship for total or LDL cholesterol.

Delivered lignan content was quantified in only six of the 13 trials, while differences in preparation, dose, duration, participant health and product composition prevented formal dose-response modelling. Using the GRADE framework, the reviewers rated the evidence as moderate certainty for the LDL-cholesterol reduction, low certainty for the total-cholesterol reduction, very low certainty for triglycerides and moderate certainty for HDL cholesterol. The LDL result was downgraded only for imprecision because its confidence interval did not extend beyond the prespecified clinically important difference of 4 milligrams per deciliter.

Evidence for total cholesterol was downgraded for risk of bias and imprecision, while the triglyceride evidence was downgraded for risk of bias, inconsistency and imprecision. Risk-of-bias assessments classified three trials as low risk, eight as raising some concerns and two as high risk. Concerns arose mainly from the randomization process and missing outcome data.

The investigators examined funnel plots and used Egger’s regression tests to assess possible small-study effects. Neither analysis provided evidence of such effects for any of the four lipid outcomes, and the pooled total- and LDL-cholesterol estimates remained statistically significant in leave-one-out analyses. These checks do not prove that publication bias was absent because both approaches have limited power with only 12 or 13 estimates.

The sensitivity analyses also showed that the triglyceride result could become significant after omitting either of two particular studies, while the overall HDL-cholesterol estimate remained nonsignificant regardless of which single study was removed. Excluding the two sunflower-oil comparator trials did not materially alter the total-cholesterol result and only slightly attenuated the LDL-cholesterol reduction. Laboratory and animal experiments offer possible explanations for the cholesterol findings but do not establish clinical effects in people.

Sesamin, a major sesame lignan, has been reported in preclinical work to inhibit cholesterol synthesis, influence intestinal absorption and promote cholesterol efflux. These proposed pathways are consistent with the possibility that sustained exposure could influence lipid metabolism, but many remain supported mainly by cell or animal evidence. The review used only human randomized evidence for its pooled results, and no included trial measured cardiovascular events such as myocardial infarction or stroke.

The findings therefore concern surrogate lipid markers, not proof that sesame prevents cardiovascular disease or provides an alternative to established lipid-lowering treatment. Several limitations constrain the conclusions. The evidence base contained only 13 trials and 690 participants, and individual studies ranged from 30 to 103 people.

Most interventions lasted five to 12 weeks, none exceeded 12 weeks, and only two directly tested purified sesamin. Nine studies were conducted in Iran, two in Japan and one each in Taiwan and Australia, limiting generalizability to other populations and dietary patterns. Seven trials used matched placebos, four used no sesame without a specific placebo, and two used sunflower oil, meaning some estimates reflected the relative effects of sesame and another dietary oil.

Most studies did not quantify the actual lignan content of their preparations, and two low-risk sesame-oil trials were funded by a sesame manufacturer. Long-term efficacy, safety, optimal dose and the effect of different processing methods remain uncertain. Overall, the review identifies sesame as a potentially useful dietary adjunct with a selective, modest effect on atherogenic cholesterol rather than a comprehensive treatment for dyslipidemia.

The strongest result was an average LDL-cholesterol reduction of about 9 milligrams per deciliter, supported by moderate-certainty evidence, while total cholesterol fell by about 12 milligrams per deciliter on lower-certainty evidence. There was no demonstrated overall benefit for triglycerides or HDL cholesterol, and the apparent advantages of longer treatment or purified sesamin remain uncertain. The authors call for larger, longer, low-risk-of-bias trials that measure bioactive compound content, compare seeds, oil and sesamin directly, recruit populations beyond the current geographic concentration and evaluate clinical cardiovascular endpoints.

Subject of Research: Effects of sesame seeds, sesame oil and sesamin on serum lipid profiles in adults

Article Title: Effects of Sesame ( Sesamum indicum L.) and Its Lignan Sesamin on the Serum Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Article References: Inthachat, W., Chupeerach, C., Trachootham, D., & Temviriyanukul, P. (2026). Effects of Sesame (Sesamum indicum L.) and Its Lignan Sesamin on the Serum Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Agriculture and Food Research, Article 103379. https://doi.org/10.1016/j.jafr.2026.103379

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103379

Keywords: sesame, sesamin, cholesterol, LDL cholesterol, triglycerides, HDL cholesterol, randomized trials, meta-analysis, lipid profile, dietary interventions, Effects, Sesamum

The index was calculated from fasting triglyceride, high-density lipoprotein cholesterol and glucose concentrations. Researchers also used receiver operating characteristic curve analysis to identify the TyHGB value that best classified participants as having high ASCVD risk. That cutoff was 8.44, but its discriminatory performance was modest: the area under the curve was 0.607, with a 95% confidence interval of 0.540–0.673. The result indicates limited ability to distinguish high-risk from lower-risk participants when TyHGB is used alone, underscoring that the observed association does not amount to strong standalone prediction.

With TyHGB treated as a continuous variable, the fully adjusted odds ratio for high ASCVD risk was 1.21 per unit increase, with a 95% confidence interval of 1.08–1.35 and P<0.001. When the index was divided at the ROC-derived cutoff, the high-versus-low comparison produced an odds ratio of 4.02, with a 95% confidence interval of 2.13–7.56 and P<0.001. These estimates describe odds within this study population at a single assessment; they do not establish the direction of causality, changes over time, or the effect of changing TyHGB. The supplied results report the significant association for the fully adjusted model rather than describing it as independently present in every sequential adjustment model.

Restricted cubic spline analysis suggested a linear dose-response relationship between TyHGB and high ASCVD risk. The test for nonlinearity returned P=0.053, meaning the study did not detect statistically significant departure from a linear pattern at the reported threshold. The result is consistent with progressively greater odds of high-risk classification across higher index values, although the cross-sectional design cannot show whether increasing the index would be followed by a change in cardiovascular risk. It also does not establish that TyHGB is a useful measure for monitoring future risk or for guiding clinical decisions.

Subgroup analyses indicated that the strength of the association varied according to two clinical characteristics. Interaction tests were significant for alcohol use, with P=0.024, and for hypertension, with P=0.041, indicating effect modification by these factors in the study analyses. The source does not establish whether TyHGB would be useful for screening or clinical decision-making, or whether the relationship applies beyond similar populations. The study’s principal contribution is the observed association in a retrospective, single-center cross-sectional analysis of adults with NAFLD, combined with evidence that the index alone distinguishes ASCVD risk categories only weakly. Because the design assesses participants at one point in time and the reported association is observational, the findings should not be interpreted as proof that changing the index would change cardiovascular outcomes. Larger prospective studies would be needed to assess whether the relationship persists over time, applies in broader populations, or provides useful information beyond other cardiovascular risk measures.

Subject of Research: Association between the TyHGB index and high atherosclerotic cardiovascular disease risk in adults with non-alcoholic fatty liver disease

Article Title: Association between the TyHGB index and the high risk of ASCVD in Chinese patients with NAFLD: a cross‑sectional study

Article References: Xiong, L., & Zhuang, H. (2026). Association between the TyHGB index and the high risk of ASCVD in Chinese patients with NAFLD: a cross‑sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02678-0

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02678-0

Keywords: TyHGB index, NAFLD, ASCVD risk, cardiovascular disease, triglycerides, glucose, cross-sectional study, odds ratio, subgroup analysis, Association, between, TyHGB

The research, published in npj Science of Food, used Soxhlet extraction to measure oil in all 169 soybean accessions. The researchers then selected two representative accessions from each of the four seed color groups for metabolomic analysis and detailed quantitative lipidomic profiling. This design separated the large-scale assessment of oil content from the more intensive molecular comparison, which involved eight accessions. The broader screening established the overall association with pigmentation, while the selected accessions were used to characterize differences in metabolic pathways and individual lipid species.

Quantitative profiling identified 650 lipid species in the eight accessions, divided among five major lipid classes and 26 subclasses. HPLC quantification showed that total lipid content decreased progressively as seed coat pigmentation increased. The differences were mainly associated with changes in triglycerides, phosphatidylethanolamines, phosphatidylcholines and phosphatidylinositols. In the broader metabolomic analysis, lipid subclasses were consistently represented among significantly altered pathways across the four color groups. These measurements show that the observed differences in oil content were accompanied by shifts in the classes and subclasses of lipids present in the seeds.

The comparison between common yellow and black soybeans produced the most specific set of differential findings: 38 lipids accumulated differently between the two groups, and pathway analysis indicated significant enrichment in sphingolipid metabolism. The study therefore links visible variation in seed coat color with both total oil content and lipid composition. Its scope should be considered carefully, however. Oil content was measured across 169 accessions, but metabolomic and quantitative lipidomic analyses were confined to two representatives from each color group. The reported results are associations among seed color groups and lipid profiles; they do not establish that pigmentation causes the differences or directly demonstrate effects on human dietary outcomes.

Subject of Research: Association of soybean seed coat pigmentation with oil content and lipidomic profiles

Article Title: Quantitative lipidomics reveals differences in oil metabolism and nutritional profiles of soybeans with various seed coat colors

Article References: Zhao, Y., Zhao, S., Li, J., Tang, F., He, L., Li, X., Su, Y., Xu, H., Du, N., Chi, H., Cheng, B., Zhang, Z., Xu, M., Tang, X., Xiao, H., Yang, W., & Liu, W. (2026). Quantitative lipidomics reveals differences in oil metabolism and nutritional profiles of soybeans with various seed coat colors. npj Science of Food. https://doi.org/10.1038/s41538-026-01195-7

Image Credits: AI Generated

DOI: 10.1038/s41538-026-01195-7

Keywords: soybean, seed coat color, oil content, quantitative lipidomics, sphingolipid metabolism, triglycerides, phosphatidylcholines, metabolomics, food chemistry, crop diversity, Quantitative, lipidomics

The study, a retrospective cohort analysis of 1,063 singleton pregnancies delivered between January and December 2024, set out to test whether TyHGB could serve as an early-warning biomarker for GDM. The index is an extension of the well-known triglyceride-glucose (TyG) index, a widely used surrogate for insulin resistance. TyHGB adds two more ingredients to the TyG formula: HDL cholesterol, the anti-inflammatory lipoprotein fraction involved in lipid regulation, and pre-pregnancy body mass index, a measure of systemic adiposity. Specifically, TyHGB is calculated as the ratio of triglycerides to HDL cholesterol, plus 0.7 times fasting plasma glucose in millimoles per liter, plus 0.1 times pre-pregnancy BMI in kilograms per square meter. Each component captures a different facet of the metabolic dysfunction that underlies GDM, which shares its core pathology — pancreatic beta-cell dysfunction and increased insulin resistance — with type 2 diabetes.

All participants underwent first-trimester blood testing before 14 weeks of gestation, with fasting venous samples analyzed for liver enzymes, total cholesterol, triglycerides, LDL and HDL cholesterol, fasting plasma glucose, and glycated hemoglobin. The women were then screened for GDM at 24 to 28 weeks using the standard 75-gram oral glucose tolerance test (OGTT), with diagnosis based on the International Association of the Diabetes in Pregnancy Study Groups criteria: fasting glucose of 92 mg/dL or higher, one-hour post-load glucose of 180 mg/dL or higher, or two-hour post-load glucose of 153 mg/dL or higher. Women with pre-existing type 1 or type 2 diabetes, multiple pregnancies, endocrine disorders, chronic hypertension, and other major complications were excluded to isolate the effect of the index in a broadly healthy obstetric population.

Of the 1,063 women enrolled, 190 — or 17.87 percent — were newly diagnosed with GDM. The median maternal age was 31 years, and the median pre-pregnancy BMI was 26.17 kg/m². When the researchers divided the cohort into tertiles based on TyHGB values, a striking gradient emerged: GDM prevalence rose from 6.59 percent in the lowest tertile to 18.72 percent in the middle tertile and 28.09 percent in the highest tertile. Women in the top tertile also carried higher triglycerides, LDL cholesterol, liver enzymes, fasting glucose, and pre-pregnancy BMI, along with lower HDL cholesterol, consistent with a broader pattern of metabolic dysregulation.

To determine whether TyHGB was an independent predictor rather than a proxy for other risk factors, the team built a series of multivariable logistic regression models with increasing levels of adjustment. In the fully adjusted model — controlling for maternal age, assisted reproductive conception, gravidity, total cholesterol, LDL cholesterol, alanine aminotransferase, aspartate aminotransferase, and glycated hemoglobin — each one-unit increase in TyHGB was associated with a 1.62-fold increase in the odds of GDM (95 percent confidence interval: 1.29 to 2.03). Compared with women in the lowest tertile, those in the highest tertile had nearly four times the odds of developing GDM (odds ratio 3.97, 95 percent CI: 2.19 to 7.21), and the dose-response relationship across tertiles was statistically significant, indicating a steady rise in risk with rising index values.

The diagnostic performance of TyHGB was then benchmarked against conventional markers using receiver operating characteristic (ROC) analysis. The area under the ROC curve (AUC) for TyHGB was 0.675 (95 percent CI: 0.646 to 0.703), with an optimal cut-off value of 5.995 determined by Youden’s index. At this threshold, the index achieved a sensitivity of 66.32 percent — correctly flagging about two-thirds of women who went on to develop GDM — and a specificity of 63.12 percent. Crucially, TyHGB outperformed maternal age (AUC 0.596), pre-pregnancy BMI (AUC 0.610), fasting plasma glucose (AUC 0.618), and the TyG index alone (AUC 0.615), suggesting that the composite formula extracts more predictive signal from the same routine blood draw than any single component could.

Subgroup analyses revealed an important nuance about who benefits most from this early signal. The association between TyHGB and GDM remained robust among women under 35 years of age, those with pre-pregnancy BMI below 25, and women who conceived spontaneously. However, in women with pre-pregnancy BMI of 25 or higher, the association was attenuated and no longer statistically significant, with a statistically significant interaction between BMI and the index. The researchers interpret this pattern as evidence that in low-risk populations — where obesity and advanced maternal age do not dominate the risk picture — subtle early glycemic and lipid disturbances are often missed by traditional screening tools, and TyHGB may fill that gap. In women already carrying strong conventional risk factors, those factors may mask the incremental value of the new index.

The biological rationale for TyHGB rests on the central role of insulin resistance in GDM. The TyG component reflects the interplay between blood glucose and triglyceride metabolism, both of which are disrupted when cells become less responsive to insulin. HDL cholesterol participates in anti-inflammatory and lipid regulatory processes, and impaired HDL function can aggravate lipotoxicity and worsen insulin resistance, further destabilizing glucose homeostasis. Pre-pregnancy BMI captures systemic adiposity, which a large-scale meta-analysis of more than 960,000 pregnant women linked to a 4 percent increase in GDM incidence per unit of BMI. By combining these parameters into a single number, TyHGB compensates for the limited accuracy of any one marker alone, and previous validation studies in Chinese and Korean populations have reported similar associations, with odds ratios ranging from 1.88 to 2.09.

The authors acknowledge several limitations. As a single-center retrospective study, the findings require external validation in larger prospective cohorts before broad clinical implementation. The study lacked data on lifestyle and socioeconomic factors such as diet, physical activity, sleep quality, and psychological status, which could influence glucose metabolism. TyHGB was measured only once, in early pregnancy, so dynamic metabolic changes across gestation were not captured. The cohort included only singleton pregnancies, and information on glucose-interfering medications was not systematically recorded. Moreover, with a moderate AUC of 0.675, TyHGB cannot serve as a standalone diagnostic test; its role is as an auxiliary tool for early risk stratification rather than a replacement for the OGTT.

Even with those caveats, the implications are significant. The current standard for GDM diagnosis — the OGTT performed at 24 to 28 weeks — arrives late in pregnancy, leaving little window for preventive intervention before complications can develop, and imposes considerable time and economic burdens on pregnant women. A simple index calculable from blood work already obtained in the first trimester could allow clinicians to flag high-risk patients months earlier, enabling targeted surveillance, individualized risk stratification, and proactive lifestyle or pharmacological measures at a stage when they may still alter the disease trajectory. Given that GDM now affects roughly 15 percent of pregnancies worldwide, with prevalence in China around 14.8 percent and regional rates ranging from 10.5 percent in Changsha to 19.7 percent in Beijing, a low-cost early screening tool could have substantial public health impact. The TyHGB index, the authors conclude, represents a promising, cost-effective, and widely applicable addition to routine antenatal screening protocols — one that could help lower GDM incidence and ultimately improve outcomes for both mothers and their babies.

Subject of Research: A composite metabolic index for predicting gestational diabetes risk in early pregnancy

Article Title: TyG indicator–TyHGB and the risk of gestational diabetes mellitus: a retrospective cohort study

Article References: Li, X., Bu, W., Liang, W., Ji, Z., Chen, Y., Xuan, Y., & Hu, X. (2026). TyG indicator–TyHGB and the risk of gestational diabetes mellitus: a retrospective cohort study. Frontiers in Nutrition, 13, Article 1967930. https://doi.org/10.3389/fnut.2026.1967930

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1967930

Keywords: gestational diabetes, TyHGB index, insulin resistance, pregnancy, first trimester screening, triglycerides, HDL cholesterol, fasting glucose, body mass index, biomarker, oral glucose tolerance test, maternal health

The research team followed PRISMA guidelines and registered their protocol in PROSPERO before searching PubMed, Scopus, and Google Scholar through April 7, 2026. The searches returned 150 records from PubMed, 679 from Scopus, and 70 from Google Scholar, from which nine observational studies comprising 1,494 participants met the inclusion criteria. Each study reported lipid parameters — high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC) — in patients stratified by tuberculosis and diabetes status. Methodological quality was appraised with the Newcastle-Ottawa Scale, and the certainty of evidence was graded using GRADE, a framework that rates confidence in findings from high to very low.

Statistically, the team used random-effects models to pool mean differences and pooled means, estimating between-study variance with restricted maximum likelihood (REML) and applying Hartung-Knapp adjustments to confidence intervals — techniques that guard against overly optimistic precision when studies are few and heterogeneous. Heterogeneity was quantified with the I² statistic and τ², and 95% prediction intervals were calculated to show where future study results might plausibly fall. In the primary comparison, patients with tuberculosis-diabetes comorbidity (TB-DM) were set against patients with tuberculosis only (TB-only); in the secondary comparison, TB-DM patients were set against those with diabetes only (DM-only).

The headline result concerns triglycerides. Compared to the TB-only group, patients with TB-DM exhibited higher concentrations of LDL-C (mean difference 14.99 mg/dL; 95% CI 1.28–28.71), TG (mean difference 30.13 mg/dL; 95% CI 17.58–42.67), and TC (mean difference 17.29 mg/dL; 95% CI 5.42–29.16). HDL-C, often called the good cholesterol, showed no significant difference between the two groups (mean difference −1.15 mg/dL; 95% CI −5.07 to 2.77). A mean difference of roughly 30 mg/dL in triglycerides is clinically meaningful, pointing toward a more atherogenic metabolic milieu when diabetes superimposes on active tuberculosis.

Yet the story is more nuanced than the headline numbers suggest. A principal sensitivity analysis showed that the triglyceride elevation remained robust, whereas the LDL-C and total cholesterol findings lost statistical significance once the analysis was stress-tested. This means the most defensible conclusion from the primary comparison is that TB-DM comorbidity is associated with higher triglycerides relative to tuberculosis alone, while the cholesterol findings should be interpreted with caution. The authors rated the overall certainty of evidence as very low across all outcomes, a reminder that observational data, however carefully pooled, cannot establish causation.

The secondary comparison flipped the direction of nearly every effect. Relative to the DM-only group, TB-DM patients exhibited significantly lower concentrations across all four lipid parameters — HDL-C, LDL-C, triglycerides, and total cholesterol. Heterogeneity in this secondary analysis ranged from just 1% to 67%, far more consistent than the substantial heterogeneity (I² greater than 70%) observed in the primary comparison. Biologically, this pattern is coherent: active tuberculosis is known to suppress appetite, impair nutrient absorption, and drive inflammatory catabolism, all of which can pull lipid levels downward even in patients whose underlying diabetes would normally push them up.

Exploratory subgroup analyses added further texture. Statistical differences were detected for LDL-C, total cholesterol, and triglycerides across subgroups, whereas no subgroup difference was found for confounder adjustment, geographic region, or study design. In other words, the lipid signal did not systematically depend on whether studies adjusted for key covariates, where they were conducted, or how they were designed — though with only nine studies, such subgroup tests have limited power. The very low GRADE rating across all outcomes underscores that these are hypothesis-generating findings rather than practice-changing conclusions.

Why do these lipid shifts matter? Triglyceride-rich lipoproteins and low HDL-C are established markers of cardiovascular risk, and diabetes already triples the likelihood of cardiovascular disease. If TB-DM patients carry a doubly dysregulated lipid profile — elevated triglycerides from the diabetic side and catabolic lipid depletion from the tuberculous side — clinicians may need to monitor cardiovascular risk more aggressively during and after tuberculosis treatment. Conversely, the finding that TB-DM patients show lower lipids than DM-only patients suggests that tuberculosis itself reshapes the metabolic landscape, potentially masking the typical diabetic dyslipidaemia and complicating risk stratification.

The study has limitations inherent to its evidence base. All nine included studies were observational, meaning confounding by age, body mass index, antidiabetic medication, antitubercular drug timing, and nutritional status cannot be excluded. The very low certainty rating reflects this, along with the substantial heterogeneity in the primary analysis. The authors also note that their search was restricted to three databases through a single cutoff date, and that publication bias — the tendency for studies with null findings to go unpublished — could not be formally ruled out with so few studies.

Nevertheless, the meta-analysis provides the most comprehensive quantitative picture to date of lipid alterations in tuberculosis-diabetes comorbidity. Its central message — that triglycerides rise when diabetes joins tuberculosis, while nearly all lipid fractions fall relative to diabetes alone — gives researchers a concrete metabolic signature to investigate in prospective cohorts. As both conditions continue to expand in overlapping geographic hotspots, from sub-Saharan Africa to South Asia, understanding how they jointly remodel blood fat metabolism could prove essential for protecting the hearts of patients already fighting on two fronts.

Subject of Research: Lipid profile alterations in pulmonary tuberculosis patients with and without diabetes mellitus: a systematic review and meta-analysis

Article Title: Lipid profile alterations in pulmonary tuberculosis patients with and without diabetes mellitus: a systematic review and meta-analysis

Article References: Yahaya, S., Goumboundi, I. A., Saahene, R. O., Dankwa, K., Acquah, S., & Ephraim, R. K. D. (2026). Lipid profile alterations in pulmonary tuberculosis patients with and without diabetes mellitus: a systematic review and meta-analysis. BMC Infectious Diseases, 26(1), Article 1727. https://doi.org/10.1186/s12879-026-14453-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14453-6

Keywords: Lipid, profile, alterations, pulmonary, tuberculosis, patients, without, diabetes, mellitus, systematic, review, meta-analysis

The research, led by Huibao Lyu, Yiting Zhang, and colleagues at Guangdong Medical University and Jieyang People’s Hospital in China, focused on the triglyceride-high-density cholesterol-glucose-body index, abbreviated as TyHGB. This index weaves together four parameters that virtually every clinic already measures: triglycerides, high-density lipoprotein cholesterol, fasting plasma glucose, and body mass index. Rather than viewing each value in isolation, the index integrates them into a single score that captures the intertwined disturbances in blood fat handling, sugar metabolism, and body composition that precede overt metabolic disease.

The study team set out to answer a question that had never been formally addressed: does a higher TyHGB score predict the future development of impaired fasting glucose, the critical prediabetic stage defined by fasting glucose between 5.6 and 6.9 millimoles per liter, in adults whose baseline glucose and lipid profiles are entirely normal? To find out, the researchers conducted a secondary retrospective analysis of a multicenter cohort, drawing on a fully anonymized, open-access dataset from the Dryad repository originally collected under ethical approval from the Rich Healthcare Group Ethics Review Board.

The scale of the analysis is striking. The investigators included 57,097 Chinese adults who were initially free of impaired fasting glucose, all of whom had baseline fasting plasma glucose below 5.6 millimoles per liter and lipid profiles below dyslipidemia thresholds. In other words, every participant started the study in the metabolic safe zone by conventional standards. The researchers calculated each person’s baseline TyHGB index from triglycerides, high-density lipoprotein cholesterol, fasting glucose, and body mass index, then tracked who developed impaired fasting glucose over time.

During a median follow-up of 2.97 years, 5,491 participants, or 9.62 percent of the cohort, developed incident impaired fasting glucose. That means nearly one in ten adults with normal baseline labs crossed into the prediabetic range within roughly three years. The central finding was unambiguous: a higher TyHGB index was significantly associated with an elevated risk of this transition. In the fully adjusted Cox proportional hazards model, each 1-unit increase in the TyHGB index carried a hazard ratio of 2.41, with a 95 percent confidence interval of 2.30 to 2.52, meaning the risk more than doubled with every unit of the index.

The quartile analysis made the gradient even more vivid. Compared with participants in the lowest quartile of the TyHGB index, those in the highest quartile faced a hazard ratio of 5.85, with a 95 percent confidence interval of 5.26 to 6.51. Adults in the top quarter of the index were nearly six times more likely to develop impaired fasting glucose than those in the bottom quarter, despite all of them beginning the study with glucose and lipid values that no clinician would flag as abnormal. The association held across prespecified subgroups, although the effect sizes varied across several clinical strata, and the results remained robust in sensitivity analyses designed to test the stability of the primary finding.

One of the most technically interesting aspects of the study involved the shape of the relationship. The researchers employed restricted cubic splines, a flexible modeling technique that allows the association between an exposure and an outcome to bend rather than forcing it into a straight line. The spline analysis revealed a significant nonlinear, piecewise relationship, with the test for nonlinearity yielding a p value below 0.001. The curve showed a threshold inflection point at a TyHGB index of 6.97. Below this value, the association between the index and impaired fasting glucose risk was comparatively gentle; above it, the risk climbed steeply. Piecewise models confirmed this threshold effect, suggesting that the index may behave less like a linear dial and more like a tripwire that marks a point of accelerating metabolic deterioration.

The biological logic behind the TyHGB index rests on the concept of insulin resistance, the metabolic state in which tissues respond sluggishly to insulin and the body compensates by pumping out more of the hormone. Elevated triglycerides combined with reduced high-density lipoprotein cholesterol form a classic lipid signature of insulin resistance, even when both values remain within the normal laboratory range. Fasting glucose reflects how well the insulin-glucose feedback loop is holding, and body mass index captures the adiposity that drives much of the metabolic disturbance. By multiplying these components together, the index amplifies the signal of subclinical metabolic dysfunction that any single parameter would miss. The study team also used the triglyceride-glucose index and its body mass index extension, known as TyG-BMI, as conceptual building blocks, and the TyHGB index represents a refinement that incorporates the protective high-density lipoprotein fraction as well.

The methodological rigor of the analysis deserves attention. The investigators adhered to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, used multivariate imputation by Chained Equations to handle missing data, checked multicollinearity with variance inflation factors, and validated the proportional hazards assumption underlying the Cox models. They also ran logistic regression models alongside the survival analyses to quantify the association in odds terms, and conducted subgroup and sensitivity analyses to evaluate the robustness of the primary associations. The study was exempt from further institutional review board approval because it used a fully anonymized public dataset, and the authors declared no competing interests and no use of generative artificial intelligence in preparing the manuscript.

The authors are careful about what their findings do and do not establish. A higher TyHGB index was associated with incident impaired fasting glucose among Chinese adults with normal baseline fasting glucose and lipid levels, but whether the index provides additional clinical value beyond conventional risk factors requires prospective validation and formal predictive-performance assessment, including receiver operating characteristic analysis of the area under the curve. The study population was Chinese, the follow-up was under three years, and the design was observational, so causation cannot be inferred. Still, the implications are compelling for a health system that routinely measures all four components of the index at negligible cost. If future prospective studies confirm the threshold behavior observed here, the TyHGB index could become a routine early-warning score, identifying adults whose normal lab reports conceal an accelerating metabolic risk long before their fasting glucose crosses the prediabetic line.

Subject of Research: Metabolic Disease

Article Title: Triglyceride-high-density cholesterol-glucose-body index and risk of impaired fasting glucose in normolipidemic adults: a secondary analysis of a multicenter cohort

Article References: Lyu, H., Zhang, Y., Lu, Y., Lin, R., Luo, Z., Li, S., Zhang, H., Yang, D., He, Q., & Zhang, L. (2026). Triglyceride-high-density cholesterol-glucose-body index and risk of impaired fasting glucose in normolipidemic adults: a secondary analysis of a multicenter cohort. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02667-3

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02667-3

Keywords: TyHGB index, impaired fasting glucose, prediabetes, insulin resistance, triglycerides, HDL cholesterol, fasting plasma glucose, body mass index, cohort study, metabolic syndrome, normolipidemic adults, risk prediction

The research, published in Physiological Reports, examined 49 healthy females aged 18 to 45 years, dividing them into three groups: those with natural menstrual cycles, those taking second-generation combined oral contraceptive pills, and those on third-generation formulations. The findings were striking. Fasting glucose concentrations were approximately 10 percent higher in second-generation pill users and roughly 12.5 percent higher in third-generation users compared to naturally cycling women. Even more dramatic, fasting triglycerides were elevated by 56 to 70 percent in pill users relative to their naturally cycling counterparts. These are not trivial differences for a population of young, healthy, normal-weight women.

What makes this study particularly valuable is the rigor with which the researchers controlled for variables that have plagued previous investigations. Earlier studies on oral contraceptives and metabolism have produced wildly inconsistent results—some reporting benefits, others harm, and still others no effect at all. The McMaster team identified several reasons for this confusion. Many prior studies failed to account for the phase of the pill cycle or menstrual cycle at which blood samples were drawn. Others compared short-term users to long-term users without accounting for the body’s adaptation over time. And critically, several lacked a proper control group of naturally cycling individuals, making it impossible to disentangle the effects of the pill from natural hormonal variation.

To address these methodological gaps, the researchers implemented what they describe as rigorous temporal controls. Participants attended two laboratory visits timed to coincide with their low-hormone and high-hormone phases. For naturally cycling women, this meant the early follicular phase (days 3 to 7) and the mid-luteal phase (approximately 7 days after ovulation, confirmed with at-home ovulation kits). For pill users, visits were scheduled during the placebo week and during the third week of active pill use—the highest hormone week for those on triphasic formulations. Blood samples were collected in a fasted state at consistent times of day, and all participants underwent dual-energy X-ray absorptiometry (DXA) scans to assess body composition with precision.

The results extended beyond glucose and triglycerides. The researchers also found that appendicular lean mass index—a measure of skeletal muscle mass in the arms and legs normalized to height—was approximately 10 percent lower in both pill-user groups compared to naturally cycling women. However, when lean mass was expressed as a percentage of total body mass rather than height, this difference disappeared, suggesting that the naturally cycling group may simply have had larger and leaner lower bodies rather than a fundamentally different muscle distribution. Leg lean mass also trended toward being lower in pill users, though this did not reach statistical significance.

One of the most intriguing findings emerged from an exploratory sub-analysis. When all participants were pooled into a single group, the researchers observed a moderate negative correlation between appendicular lean mass index and fasting glucose concentrations—but only during the high-hormone phase. This suggests that skeletal muscle mass may play a more active role in glucose regulation during certain hormonal contexts than previously appreciated. Skeletal muscle is responsible for as much as 75 percent of glucose uptake from the bloodstream following a carbohydrate-containing meal, making it a critical player in metabolic health. Previous research has shown that lower muscle mass predicts impaired fasting glucose in elderly women, and the current findings hint that this relationship may extend to younger populations under specific hormonal conditions.

The mechanisms behind these metabolic differences likely involve the synthetic estrogen ethinyl estradiol, which is contained in both second- and third-generation oral contraceptives. Endogenous 17β estradiol—the naturally produced form of estrogen—plays a beneficial role in energy metabolism. It facilitates insulin secretion, stimulates glucose uptake from the bloodstream, reduces hepatic glucose release, promotes the shift from lipid storage to lipid oxidation, and lowers circulating triglyceride concentrations. Crucially, chronic exposure to ethinyl estradiol dramatically suppresses the body’s own estrogen production. The researchers previously confirmed that circulating 17β estradiol concentrations were significantly lower in both pill-user groups compared to naturally cycling women during the high-hormone phase. It is therefore plausible that pill users simply had less natural estrogen available to perform these metabolic protective functions.

The divergence between pill generations adds another layer of complexity. Third-generation users had approximately 40 percent higher HDL cholesterol concentrations compared to second-generation users, and there was a trend toward a lower total cholesterol to HDL ratio in the third-generation group. This difference likely relates to the type of progestin used in each formulation. Second-generation pills contain androgenic progestins that may antagonize the lipid effects of ethinyl estradiol, while the less androgenic progestins in third-generation pills may instead enhance them. This finding underscores the importance of distinguishing not just between pill users and non-users, but between different generations and formulations of the pill itself.

Importantly, the researchers caution that the magnitude of these differences, while statistically significant, remains modest in absolute terms. Average fasting glucose in all three groups remained well below the clinical threshold for concern, and only one participant across the entire study met the criteria for metabolic syndrome. For young, healthy, normal-weight women, the pill is unlikely to meaningfully increase the risk of developing metabolic disease. However, the researchers note that these subtle shifts could become clinically relevant for individuals with preexisting risk factors. A woman whose fasting glucose sits at 5.1 millimoles per liter before starting the pill, for example, could cross the threshold into the elevated range with the kind of increase observed in this study.

As metabolic syndrome rates continue to rise worldwide—particularly among women aged 18 to 45, the demographic most likely to use oral contraceptives—these findings carry significant public health implications. They also suggest that researchers may need to reconsider how they design studies involving female participants. Rather than excluding pill users to control for hormonal variability, the authors propose that expanding eligibility criteria to include both naturally cycling women and pill users could actually increase female participation in physiological research while improving the relevance and generalizability of the results. Future work, they note, should also examine how newer long-acting hormonal contraceptives, such as hormonal intrauterine devices, influence metabolism and body composition, as their popularity has surged over the past decade.

Subject of Research: The effects of combined oral contraceptive pills on fasting glucose, lipid metabolism, and body composition in young healthy females

Article Title: Elevated fasting glucose and triglycerides in combined oral contraceptive users compared to naturally cycling females

Article References: Karaguesian, C., Williams, J. S., MacDonald, M. J., & Bell, K. E. (2026). Elevated fasting glucose and triglycerides in combined oral contraceptive users compared to naturally cycling females. Physiological Reports, 14(19), Article e71135. https://doi.org/10.14814/phy2.71135

Image Credits: AI Generated

DOI: 10.14814/phy2.71135

Keywords: oral contraceptives, fasting glucose, triglycerides, metabolic syndrome, estrogen, body composition, HDL cholesterol, insulin resistance, menstrual cycle, women's health, DXA, skeletal muscle

The choice of metabolic biomarkers also deserves attention. Rather than relying solely on conventional lipid measures, the study included leptin and adiponectin, two adipokines that reflect adipose tissue function and insulin sensitivity. Leptin is produced proportionally to fat mass and signals satiety to the hypothalamus, but in states of excess adiposity, circulating leptin rises while cellular responsiveness diminishes, a phenomenon known as leptin resistance. Adiponectin, by contrast, is an insulin-sensitizing hormone whose levels tend to fall as visceral fat accumulates. The ratio between these two hormones has been proposed as a sensitive indicator of metabolic dysfunction in children, sometimes detecting disturbances earlier than changes in body mass index or standard lipid panels become apparent. Fructosamine, meanwhile, offers a practical alternative to fasting glucose measurements in studies where blood is drawn without regard to meal timing. Because fructosamine reflects the glycation of serum proteins over the preceding two to three weeks, it provides an integrated picture of recent glycemic control without requiring participants to fast, which is a considerable logistical advantage in pediatric research.

The observation that associations differed by pubertal stage is scientifically meaningful for several reasons. Puberty is characterized by profound hormonal shifts, including rising concentrations of sex steroids and growth hormone, both of which influence lipid metabolism. Growth hormone, for instance, tends to raise LDL cholesterol and lower insulin sensitivity during mid-puberty, while estrogen in girls generally improves lipid profiles by raising HDL cholesterol. These physiological changes create a moving baseline against which any environmental effect must be measured. If a chemical perturbs lipid metabolism, its apparent impact may be amplified, attenuated, or masked depending on the pubertal context in which exposure is assessed. The finding that perfluorononanoic acid and perfluorodecanoic acid were linked to higher triglycerides in peripubertal boys, while perfluorooctane sulfonate showed an inverse association with triglycerides in postpubertal boys, illustrates this complexity. Such direction reversals across developmental stages have been reported in other cohorts and may reflect genuine biological differences in how PFAS interact with maturing endocrine systems, or alternatively may arise from changes in PFAS body burden during puberty, since these chemicals bind to serum proteins and their apparent concentrations can be influenced by shifts in blood volume and body composition as children grow.

The pharmacokinetics of PFAS in children are relevant to interpreting these results. Long-chain PFAS compounds have elimination half-lives in humans that range from several years for perfluorooctane sulfonate to roughly four to five years for some perfluorinated carboxylic acids, and even longer for certain longer-chain analogues. This means that serum levels measured at age 12 partly reflect exposures accumulated over years, and in the case of the longest-lived compounds, may still carry a contribution from prenatal and early-life exposure transferred through the placenta and through breastfeeding. Because the PELAGIE cohort collected cord blood and childhood samples at earlier follow-ups, future analyses from this same population can help disentangle whether metabolic associations at age 12 are driven by concurrent exposure, by earlier life exposure, or by the cumulative burden of both. This is precisely the kind of question that cross-sectional data alone cannot resolve, and it underscores the authors’ call for longitudinal follow-up.

The detection of PFAS in every serum sample examined is consistent with biomonitoring surveys conducted across Europe and North America, which consistently find near-universal presence of perfluorooctane sulfonate, perfluorooctanoic acid, and perfluorohexane sulfonate in blood serum. These three compounds were among the most heavily produced PFAS historically and remain widespread despite phase-outs and restrictions, owing to their extreme persistence, their continued presence in the environment, and in some cases ongoing production in parts of the world where regulations are less stringent. Perfluorooctane sulfonate has been listed under the Stockholm Convention on Persistent Organic Pollutants, and perfluorooctanoic acid has been the subject of international restrictions as well, yet both remain detectable in human serum decades after their peak production. The longer-chain perfluorinated carboxylic acids examined in this study, such as perfluoroundecanoic acid and perfluorodecanoic acid, are less well characterized in the epidemiological literature, partly because they were produced in smaller volumes and measured less frequently in earlier studies. Their emergence as the compounds most consistently associated with lipid markers in this cohort highlights the value of measuring a broader panel of PFAS rather than focusing only on the legacy compounds.

Several mechanisms have been proposed to explain how PFAS might influence lipid metabolism. These compounds activate peroxisome proliferator-activated receptors, a family of nuclear receptors that regulate fatty acid oxidation, adipogenesis, and lipid storage. Experimental studies in rodents and in human cell models have shown that PFAS exposure can alter expression of genes involved in cholesterol synthesis and transport, mitochondrial fatty acid metabolism, and bile acid homeostasis. Some PFAS also interact with other nuclear receptors involved in endocrine signaling, raising the possibility that their metabolic effects are mediated partly through interference with thyroid hormone action, since thyroid status strongly influences lipid profiles in growing children. Whether these mechanisms operate similarly in preadolescents as in adults remains an open question, and the sex-specific patterns observed in this study may reflect differences in hormonal milieu, body composition, or PFAS clearance between boys and girls.

The non-fasting design of the blood collection warrants brief consideration when interpreting the lipid findings. Triglyceride concentrations in particular are sensitive to recent food intake, and non-fasting measurements can introduce variability that fasting protocols would avoid. However, growing consensus in pediatric lipidology supports the use of non-fasting lipid profiles for routine screening, since postprandial changes in total cholesterol, HDL, and LDL are generally modest, and non-fasting sampling reflects the metabolic state in which children spend most of their time. The use of the Friedewald equation to derive LDL cholesterol is standard practice, though it becomes less accurate at very high triglyceride concentrations, a situation unlikely to be common in a healthy cohort of twelve-year-olds.

It is also worth noting the strengths and limitations inherent in the study design. The PELAGIE cohort offers the advantage of detailed prospective data collection from early pregnancy onward, allowing careful adjustment for factors such as maternal characteristics, socioeconomic variables, and child diet and physical activity, all of which can confound associations between chemical exposure and metabolic health. The sample size of 451 children is respectable for a single-region birth cohort, though stratification by both sex and pubertal stage reduces the number of participants in each subgroup analysis, which can limit statistical precision and increase the possibility that some findings reflect chance. Cross-sectional designs, by their nature, cannot establish temporal ordering between exposure and outcome, and reverse causation remains a theoretical concern, since body size and body composition can influence PFAS serum concentrations through dilution and volume of distribution effects. Children with higher adiposity may show lower serum PFAS concentrations per unit of exposure simply because the same body burden is distributed across a larger volume, a phenomenon that has been documented in prior studies and that could bias observed associations in either direction.

From a public health perspective, the study reinforces the rationale for reducing PFAS exposure during childhood, a period when the developing cardiovascular and endocrine systems may be particularly susceptible to chemical perturbation. Regulatory actions in the European Union and elsewhere have increasingly targeted entire classes of PFAS rather than individual compounds, reflecting recognition that the thousands of substances in this chemical family share structural features and persistence. Dietary interventions, such as reducing consumption of food packaged in greaseproof materials, and household measures, such as filtering drinking water where contamination is known, represent practical steps families can take, though the ubiquity of these chemicals means that individual-level avoidance has limits. The findings from this French cohort, together with converging evidence from other populations, support continued biomonitoring and longitudinal research to clarify whether the metabolic associations observed at age twelve translate into measurable cardiovascular risk as these children mature into adolescence and adulthood.

Subject of Research: Association between PFAS exposure and metabolic biomarkers in 12-year-old children

Article Title: PFAS exposure in 12-year-old children and its association with metabolic markers

Article References: Lejeune, N., Rouxel, E., Monfort, C., Tillaut, H., Goxe, C., Rouget, F., Giton, F., Gaudreau, É., Lainé, F., Garlantézec, R., Cordier, S., Chevrier, C., & Warembourg, C. (2026). PFAS exposure in 12-year-old children and its association with metabolic markers. Pediatric Research. https://doi.org/10.1038/s41390-026-05396-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05396-4

Keywords: PFAS, children, metabolic markers, cholesterol, puberty, PELAGIE cohort, lipids, environmental health, endocrine disruptors, triglycerides, exposure, year-old

The research team, led by Ting Yuan, Peter Mirtschink, and Jaya Krishnan, focused on a long-standing puzzle in obesity biology. As white adipose tissue expands under chronic nutrient overload, the enlarging adipocytes frequently outgrow their vascular supply, leaving the tissue poorly oxygenated. This local hypoxia is a well-documented hallmark of obesity and has been linked to inflammation, fibrosis, and impaired insulin sensitivity. HIF1α, the master transcriptional regulator of the hypoxic response, accumulates in the adipocytes of obese humans and mouse models, but its precise metabolic role in mature fat cells has remained incompletely defined—partly because earlier studies produced seemingly contradictory results depending on whether researchers examined adipocyte differentiation or fully differentiated cells.

Recent work by Kudo and colleagues in 2023 helped resolve this confusion by demonstrating that HIF1α exerts state-dependent effects: it inhibits early adipocyte differentiation but promotes lipid accumulation in mature, PPARγ-competent adipocytes. The new study builds directly on that framework, but goes further by restricting its analysis to differentiated adipocytes under nutrient excess and hypoxic stress, deliberately excluding preadipocytes and adipose tissue development. The authors emphasize that all mechanistic conclusions from their work apply only to mature, PPARγ-competent adipocytes and should not be extrapolated to adipogenesis or tissue expandability.

To dissect the mechanism in vivo, the researchers generated adipocyte-specific Hif1α knockout mice by crossing mice carrying loxP-flanked Hif1α alleles with Fabp4/aP2-Cre transgenic mice, which drive recombination in both white and brown adipocytes. The resulting conditional knockout animals showed roughly 90 percent downregulation of Hif1α mRNA in white adipose tissue, with corresponding repression of canonical HIF1α target genes including Glut1, aldolase A1, and Vegfα, while the non-HIF1α target Glut4 remained largely unaffected. The knockout mice were born at the expected Mendelian ratio, had comparable bodyweights to littermate controls on a normal chow diet, and displayed no overt phenotype under baseline conditions.

The dramatic differences emerged only under metabolic stress. When both groups were maintained on a high-fat diet containing 58 percent of calories from fat for 25 weeks, the Hif1α conditional knockout mice gained significantly less weight and adiposity than their wild-type counterparts, with differences detectable as early as four weeks into the diet. Crucially, the reduced fat mass was not accompanied by a lipodystrophic phenotype: the liver and skeletal muscles of the knockout mice showed comparable weights, gross morphologies, and lipid content to controls, indicating that the protective effect was confined to the adipose tissue itself rather than reflecting ectopic fat redistribution.

Metabolic testing revealed equally striking systemic benefits. Glucose tolerance tests showed that while both groups responded comparably on a normal chow diet, the Hif1α knockout mice on the high-fat diet demonstrated significantly improved glucose handling. Insulin tolerance tests confirmed the effect: wild-type mice on the high-fat diet showed minimal blood glucose response to an insulin bolus, whereas the knockout mice maintained normal peripheral insulin sensitivity. Glycated hemoglobin values were consistently lower in the knockout animals, indicating sustained improvements in average blood glucose over time.

Histological analysis pinpointed the cellular basis of these improvements. The adipocytes of Hif1α knockout mice on the high-fat diet were approximately 50 percent smaller than those of wild-type controls, though comparable in number. Oil red O staining and direct triacylglycerol content measurements confirmed reduced lipid accumulation within the smaller cells. The researchers concluded that Hif1α is dispensable for adipocyte formation per se but is required for stress-induced lipid storage in mature adipocytes engaged in nutrient overload—a distinction that separates adipocyte differentiation from hypertrophic expansion.

The mechanistic core of the study lies in the identification of a specific enzymatic axis as the molecular executor of HIF1α-dependent lipid rechanneling. The researchers found that nutrient overload induced significant increases in the enzymatic activities of glycerol-3-phosphate dehydrogenase 1 (GPD1) and glycerol-phosphate acyltransferase (GPAT) in wild-type adipose tissue, but that inactivation of Hif1α prevented this induction. GPD1 catalyzes the first step of the glycerolipid biosynthetic pathway, converting dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate, while GPAT represents the rate-limiting step for de novo triacylglyceride synthesis. Both enzymes are downstream targets of PPARγ, the master transcriptional regulator of lipid anabolic gene expression in adipocytes.

Isotope-based metabolic flux analyses provided direct biochemical confirmation of the rechanneling hypothesis. The researchers added radiolabeled carbon-1 glucose to adipose tissue explants and tracked its incorporation into stored triacylglycerides. In wild-type tissue under nutrient overload, carbon-1 incorporation into triacylglycerides was significantly enhanced, reflecting preferential channeling of the glycolytic intermediate DHAP toward lipid synthesis. In Hif1α knockout tissue, this incorporation was markedly reduced. The researchers also measured enzymatic activities along the canonical glycolytic branch—glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH)—and found both markedly reduced in knockout tissue, confirming that Hif1α coordinates engagement of the glycolytic and glycerolipid biosynthetic branches simultaneously rather than acting on one pathway in isolation.

The study also identified a plausible redox-based mechanism that could stabilize this coordinated flux. GAPDH-mediated glycolysis consumes NAD+ and generates NADH, whereas GPD1-driven glycerol-3-phosphate production consumes NADH and regenerates NAD+. This reciprocal use of redox cofactors provides a self-sustaining loop that allows high flux through both pathways simultaneously in hypertrophic adipocytes under hypoxic conditions, preventing redox imbalance while favoring continued glycolytic throughput. The researchers suggest that this redox coupling may explain how hypoxic adipocytes sustain lipid synthesis despite limited oxygen availability for oxidative metabolism.

The findings carry significant implications for understanding obesity-related metabolic dysfunction. By identifying the GPD1–GPAT axis as the enzymatic executor of the late-stage HIF1α–PPARγ lipid storage program, the study provides in vivo metabolic validation for a model that had previously been supported primarily by transcriptional and cell-culture evidence. It also offers a unified mechanistic explanation for decades of observations linking hypoxia with enhanced lipid synthesis in adipose and other metabolic tissues. The authors caution that their results do not imply HIF1α universally promotes adipose tissue growth; rather, the prolipogenic effects are gated by adipocyte differentiation state and depend on the presence of an established PPARγ transcriptional network. In preadipocytes or during early lineage commitment, sustained HIF1α activation has been shown to impair adipogenesis and limit tissue expandability. The study thus establishes HIF1α as a state-dependent metabolic integrator rather than a universal driver of adipose tissue expansion, refining the framework for future therapeutic strategies targeting hypoxic signaling in obese{

Subject of Research: Molecular metabolism

Article Title: HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes

Article References: Zhu, C., Wu, M., Pham, M. D., Wang, Y., Das, A. P., Mao, Y., Mirtschink, P., Yuan, T., & Krishnan, J. (2026). HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes. Frontiers in Molecular Medicine, 6, Article 1716464. https://doi.org/10.3389/fmmed.2026.1716464

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1716464

Keywords: HIF1α, PPARγ, adipocytes, obesity, hypoxia, triglycerides, GPD1, GPAT, insulin sensitivity, metabolism, HIF1, reinforces

The research team, led by Meng Zhou and Mengxuan Qiao of the Affiliated Mental Health Center and Hangzhou Seventh People’s Hospital at Zhejiang University School of Medicine, together with colleagues at West China Hospital of Sichuan University and a nationwide network known as the Chinese Antipsychotics Pharmacogenomics Consortium, conducted a post hoc analysis of a multicenter randomized clinical trial. Rather than treating all patients with acute schizophrenia as a single homogeneous population, the investigators applied K-means clustering, an unsupervised machine learning technique that groups individuals according to the similarity of their symptom profiles. The algorithm, working on baseline symptom data, sorted the nearly 3,000 patients into three clearly separable clusters, each with a distinct clinical signature.

The first subgroup, comprising 1,010 patients, was characterized by predominant negative symptoms — the draining, deficit-like features of schizophrenia that include social withdrawal, blunted emotional expression, apathy, and reduced motivation. The second and largest subgroup, with 1,226 patients, was dominated by positive symptoms such as hallucinations and delusions, but with a comparatively lower overall severity of illness. The third subgroup, 754 patients strong, was globally severe: these patients carried high levels of both positive and negative symptoms and represented the most profoundly ill segment of the cohort. This kind of data-driven stratification matters because schizophrenia is notoriously heterogeneous; two patients sharing the same diagnosis can present with almost non-overlapping symptom pictures, and that variability has long frustrated attempts to predict who will benefit from a given medication.

When the researchers examined baseline metabolic measures across the three clusters, striking differences emerged. Patients in the negative symptom-predominant cluster had significantly higher levels of triglycerides and low-density lipoprotein cholesterol, the lipoprotein fraction commonly branded as bad cholesterol because of its association with cardiovascular disease. Conversely, patients in the globally severe cluster showed higher levels of high-density lipoprotein cholesterol, the so-called good cholesterol. These were not subtle statistical whispers buried in noise; the lipid separations aligned with the clinical separations, raising the possibility that the metabolic state of a patient at the moment of hospitalization is not random background noise but part of the biology that defines their subtype of illness.

The clinical consequences of this stratification became apparent over the six-week treatment period. Using logistic regression to model treatment response and mixed-effects models to track longitudinal symptom trajectories, the team showed that both the likelihood of responding to antipsychotic medication and the shape of symptom improvement over time differed significantly across the three subgroups. In other words, the trajectory of recovery was not a single curve with patients scattered around it, but multiple distinct curves corresponding to the distinct clinical phenotypes. This finding reinforces a growing consensus in biological psychiatry: symptom dimensions, rather than diagnosis alone, may be the more informative unit for predicting and personalizing treatment.

The most consequential result, however, came from the mediation analyses. The researchers asked a specific causal-adjacent question: could the metabolic differences between subgroups statistically account for some of the differences in treatment response between those same subgroups? The answer was yes for LDL-C. Low-density lipoprotein cholesterol significantly mediated the subgroup-related differences in short-term clinical outcomes, meaning that a measurable portion of the variability in how patients improved could be traced through their baseline LDL-C levels. Triglycerides and HDL cholesterol, while differentially distributed across clusters, did not emerge as significant mediators in the same way. The effect is partial, not total — LDL-C explains some, but by no means all, of the heterogeneity — yet even a partial mechanistic bridge between a routine blood test and psychiatric drug response is a rare and valuable finding.

Why might LDL cholesterol be entangled with antipsychotic response? The study itself does not establish a biological mechanism, and the authors are careful to frame the mediation as a statistical association rather than proof of causation. But the result sits within a broader scientific context that makes it plausible. Cholesterol is a fundamental component of neuronal membranes and is heavily involved in synaptic function, myelination, and the organization of neurotransmitter receptors, including the dopamine and serotonin receptors that antipsychotic drugs target. Lipids also serve as precursors and signaling molecules in inflammatory pathways, and low-grade inflammation has repeatedly been implicated in both the negative symptoms of schizophrenia and poor treatment outcomes. Furthermore, many antipsychotics themselves have pronounced metabolic effects, altering lipid metabolism and weight, which creates a bidirectional web connecting the drugs, the metabolism, and the symptoms. A patient’s lipid status at baseline could therefore plausibly shape both the biology of their illness and the pharmacology of their recovery.

The practical implications are tantalizing but must be handled with appropriate caution. If baseline LDL-C genuinely contributes to treatment heterogeneity, then a simple, inexpensive blood draw — already routine in most psychiatric admissions for metabolic monitoring — could eventually become part of a prediction model that helps clinicians anticipate which patients are likely to respond poorly and might need closer follow-up, earlier dose adjustments, or adjunctive strategies. The subgroup framework itself could sharpen clinical trials: if future studies stratify enrollment by symptom cluster, they may reduce the noise that has historically diluted effect sizes in schizophrenia research. At the same time, this was a post hoc analysis, meaning the subgroups and mediation pathways were explored in existing trial data rather than pre-registered hypotheses tested in a fresh sample. Mediation analysis in observational contexts can be sensitive to model assumptions, and the six-week window captures short-term response rather than the long-term outcomes that matter most to patients and families.

There is also the question of generalizability. The trial was conducted across multiple centers in China through the Chinese Antipsychotics Pharmacogenomics Consortium, and while the large sample size of 2,990 patients lends considerable statistical power, lipid distributions, dietary patterns, antipsychotic prescribing habits, and metabolic risk all vary across populations. Replication in independent cohorts from other regions, ideally with prospective designs that pre-specify the symptom clusters and lipid markers, will be essential before LDL-C earns a place in clinical decision-making. The open-access study, funded in part by the National Natural Science Foundation of China and the China Brain Project, has been released with its full methodological detail to make such replication easier.

Even with those caveats, the study lands at a moment when psychiatry is actively searching for biomarkers that can cut through diagnostic fuzziness. The idea that a standard lipid panel might carry information about both the shape of a patient’s illness and their likely response to treatment reframes schizophrenia as a condition in which metabolism and mind are not parallel tracks but a single braided biology. It also adds urgency to the metabolic care of people with schizophrenia, a population that already bears a disproportionate burden of cardiovascular disease and whose physical health is too often an afterthought in psychiatric settings. If future work confirms and extends the link between LDL cholesterol and treatment response, the humble cholesterol test could become an unexpected ally in the quest to match the right patient with the right medication at the right time — turning one of psychiatry’s oldest frustrations into a solvable measurement problem.

Subject of Research: Lipid profiles as mediators of symptom-subgroup differences in antipsychotic treatment response in acute schizophrenia

Article Title: Lipid profiles and treatment response across symptom-based subgroups in acute schizophrenia: a post-hoc analysis of a randomized clinical trial

Article References: Zhou, M., Qiao, M., Wang, Q., Li, M., Ren, H., Ni, P., Deng, W., Guo, W., Zhang, Y., Li, T., & Chinese Antipsychotics Pharmacogenomics Consortium (2026). Lipid profiles and treatment response across symptom-based subgroups in acute schizophrenia: a post-hoc analysis of a randomized clinical trial. Schizophrenia. https://doi.org/10.1038/s41537-026-00808-0

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00808-0

Keywords: schizophrenia, lipids, LDL cholesterol, antipsychotics, treatment response, K-means clustering, biomarkers, metabolic syndrome, negative symptoms, randomized clinical trial, precision psychiatry, triglycerides